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Summary 1 
Hand-foot-and-mouth disease is a common childhood illness primarily caused by 2 
coxsackievirus A16 (CVA16), for which there are no current vaccines or treatments. We 3 
identify three CVA16-specific neutralizing monoclonal antibodies (nAbs) with therapeutic 4 
potential, 18A7, 14B10, and NA9D7. We present atomic structures of these nAbs bound 5 
to all three viral particle forms -- the mature virion, A-particle forming upon receptor 6 
engagement, and empty particle-- and show that each Fab can simultaneously occupy 7 
the mature virion. Additionally, 14B10 or NA9D7 provide 100% protection against lethal 8 
CVA16 infection in a neonatal mouse model. 18A7 binds to a non-conserved epitope 9 
present in all three particles, whereas 14B10 and NA9D7 recognize broad protective 10 
epitopes but only bind the mature virion. NA9D7 targets an immunodominant site, which 11 
may overlap the receptor binding site. These findings indicate that CVA16 vaccines 12 
should based on mature virions and that these antibodies  could be used to discriminate 13 
optimal virion-based immunogens. 14 
Keywords: coxsackievirus A16, cryo-EM structure, therapeutic antibody, vaccine design15 
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Introduction 16 
The coxsackievirus A16 (CVA16), a non-enveloped, single-stranded RNA picornavirus 17 
belonging to the Picornaviridae family, is the dominant pathogen of hand, foot, and 18 
mouth disease (HFMD) inflicting infants and younger children worldwide(Fields et al., 19 
2007). Since the first outbreak of CVA16-associated HFMD in Canada in 1957(Robinson 20 
et al., 1958), CVA16 infections have spread to Asia, Africa, Europe, and South America, 21 
where severe complications and fatal cases have been reported(CHANG et al., 1999; 22 
Wang et al., 2004). Furthermore, CVA16 can co-circulate and co-infect with other 23 
enteroviruses such as enterovirus 71 (EV71), another major pathogen of HFMD, leading 24 
to serious clinical outcomes and viral genetic recombination(Liu et al., 2014; Mao et al., 25 
2014). Although effective inactivated EV71 vaccine has been recently marketed, it 26 
cannot provide cross-protection against CVA16 infection(Li et al., 2016; Li et al., 2014; 27 
Zhu et al., 2014; Zhu et al., 2013), and no antiviral therapy or vaccine is available for 28 
CVA16. This underscores the necessity and urgency to develop an effective treatment 29 
for CVA16 infection. 30 
Picornaviruses generally undergo numerous structural transitions during their life 31 
cycle; several different particle types—procapsid, mature virion, A-particles and empty 32 
particles—have been isolated and well-characterized. These particles are different in 33 
component, structure, and immunogenicity, and therefore, vaccine development needs 34 
to consider the particulate form that would act best as an effective vaccine 35 
immunogen(Baggen et al., 2018; Ren et al., 2013; Ren et al., 2015; Wang et al., 2012; 36 
Xu et al., 2017; Zheng et al., 2019; Zhu et al., 2018a; Zhu et al., 2018c). For poliovirus, 37 
two distinct antigenic forms exist, designated C-antigens and D-antigens. The C-antigen 38 
is found on A-particles and empty particles, whereas the D-antigen is expressed on the 39 
mature virion and is regarded as a more potent immunogen for vaccine 40 
development(Ferguson et al., 1993). Indeed, previous immunological characterizations 41 
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have shown that the CVA16 mature virion can induce a higher neutralizing antibody titer 42 
than the empty particle(Chong et al., 2012), suggesting that it may contain the major 43 
immunodominant epitope(s) and that its abundant content will influence the 44 
effectiveness of a CVA16 vaccine.  45 
Vaccines usually prevent virus infection by inducing high-titers of potent 46 
neutralizing antibodies (nAbs); antibody epitopes on the virus, in turn, serve as structure 47 
templates for the rational design or selection of appropriate vaccine immunogens. The 48 
enterovirus must transition from a mature virion to an A-particle to penetrate the cell 49 
membrane and release its genome into the cytosol of the host cell (Baggen et al., 2018; 50 
Shingler et al., 2013). Such transitions are accompanied by structural rearrangement 51 
and changes in particle antigenicity(Zheng et al., 2019; Zhu et al., 2018c). For the 52 
picornaviruses EV71, CVA10, EVD68 and HRV, some nAbs show cross-reactivity to the 53 
different conformational states of the viral particles(Dong et al., 2017; Plevka et al., 54 
2014; Zheng et al., 2019; Zhu et al., 2018b; Zhu et al., 2018c). However, there is no 55 
structural information available in the literature regarding the immune-complex or viral 56 
neutralization epitopes for CVA16. Given that different CVA16 particle states display 57 
antigenic diversity, it remains unclear whether nAbs recognize a specific CVA16 viral 58 
conformation or define a common site that must remain intact during capsid 59 
transformation. 60 
Here, we systematically analyzed the functional properties of three CVA16 61 
nAbs—18A7, 14B10 and NA9D7—and identified the molecular basis of nAb-mediated 62 
neutralization for CVA16. We show that 18A7 neutralizes only restricted strains of 63 
CVA16 and binds to the viral 5-fold vertex of all three types of the CVA16 particle. In 64 
contrast, 14B10 and NA9D7 both exhibit broad neutralization activities and therapeutic 65 
potential against CVA16 infection but bind exclusively to mature virions surrounding viral 66 
3-fold and 2-fold axes, respectively. These results support the use of CVA16 mature 67 
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virions for vaccine development, and an assay based on antibodies 18A7 and NA9D7 68 
allows the quantification of immunogen constituents. 69 
Results 70 
Characterization of anti-CVA16 nAbs 18A7, 14B10, and NA9D7 71 
To investigate the antibody-mediated neutralization of CVA16 and the antigenic profiles 72 
across different particle forms, we selected three murine nAbs for functional and 73 
structural analysis: two nAbs, 18A7 and 14B10, were developed in this study; one nAb, 74 
NA9D7, from a panel of 48 murine mAbs in our previous work(Ye et al., 2016). Prior to 75 
structure determination at high-resolution, these three nAbs were identified to bind 76 
distinct regions of CVA16 capsid by a preliminary cryo-EM analysis. First, using a 77 
binding assay with various viral particle forms, we found that 18A7 exhibits comparable 78 
binding efficiency to full particles (including genomic RNA) and empty particles, whereas 79 
14B10 and NA9D7 bind preferentially to full particles (Figures S1A-S1C). Through cell-80 
based neutralization assays using a local epidemic strain, CVA16/190 (GenBank 81 
accession no. KJ850274, also used for the subsequent structural analysis), we found 82 
that 18A7 possessed higher neutralizing activity than 14B10 and NA9D7, with half-83 
maximum inhibitory concentrations (IC50) of 0.04, 1.01, and 1.96 μg/mL, respectively 84 
(Figures 1A, 1B and S1D). Further neutralization assays showed that 18A7 could 85 
neutralize 213a and 4430 strains but not the 4479 strain, while14B10 and NA9D7 could 86 
neutralize all three strains but with a lower efficacy than 18A7 (Figures 1A, 1B and S1D).  87 
We next sought to assess the correlation between in vitro neutralization and in 88 
vivo protection. Inoculation with either 14B10 or NA9D7 provided 100% protection 89 
against lethal infection with CVA16 in a neonatal mouse model at a dosage of 3 μg/g, 90 
whereas 18A7 generated no protection, even at a 10-fold higher dosage (30 μg/g) 91 
(Figure 1C). The inconsistent outcome that nAb 18A7 neutralized CVA16 in human RD 92 
cell model whereas provided no protection in mouse might result from some different 93 
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host factors, of which human SCARB2 and PSGL-1 were identified as CVA16 receptors, 94 
but in contrast murine ones exhibited no such function in the mouse model(Nishimura et 95 
al., 2009; Yamayoshi et al., 2009). Fluorescence-based thermal stability assays revealed 96 
a ~1°C higher melting temperature when the full particle was bound with the 18A7 Fab 97 
fragment or full-length antibody as compared with the unbound full particle (Figure 1D). 98 
In contrast, 14B10 Fab and the full-length antibody stabilized the full particle by 10°C 99 
and 1.8°C, respectively, and NA9D7 Fab and the full-length antibody stabilized the full 100 
particle by 2.5°C or 1.8°C, respectively (Figure 1E and 1F). These results indicate that 101 
virions exhibited enhanced thermal stability through engagement with either the Fab or 102 
the full-length antibody for all three nAbs, with a particular efficacy observed in the 103 
14B10 Fab. Overall, these findings show the differences in interaction characteristics of 104 
the three nAbs and suggest distinct mechanisms of virus neutralization. 105 
Purified full and empty particles of CVA16 were separately subjected to cryo-EM 106 
inspection and 2D classification for structural analysis. The full particle fraction was 107 
primarily composed of mature virions (CVA16-M, 73% occupancy in total particles) with 108 
some A-particles (CVA16-A, 14%) and empty particles (CVA16-E, 13%). Comparatively, 109 
the CVA16 empty particle fraction nearly exclusively consisted of empty particles 110 
(Figures S2A and S2B). Other enterovirus studies(Fan et al., 2017; Zhu et al., 2018a)  111 
also confirmed the coexistence of three particle forms in purified fractions. The CVA16 112 
full particle fraction was complexed separately with Fab 18A7, 14B10, or NA9D7 for 113 
cryo-EM structure reconstruction. In line with the binding profiles of the three nAbs 114 
(Figures S1A-S1C), 18A7 bound to all three types of CVA16 particles (Figures S2C-115 
S2E) with structures resolved at 2.65 Å, 3.07 Å, and 3.13 Å for CVA16-M:18A7, 116 
CVA16:A-18A7, and CVA16-E:18A7, respectively (Figures 2A-2C, S3, S4D-S4F, Table 117 
1 and Video S1). Contrastingly, 14B10 and NA9D7 exclusively bound to mature virions, 118 
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with structures of CVA16-M:14B10 and CVA16-M:NA9D7 solved at 3.30 Å and 3.23 Å, 119 
respectively (Figures 2D, 2E, S2F-S2K, S4G, S4H, Table 1, Videos S2 and S3).  120 
The density maps of the three 18A7-bound immune complexes show that a 121 
single 18A7 Fab engages one 5-fold vertex of the icosahedral capsid and therefore only 122 
12 Fabs can bind to each viral particle (Figures 2A-2C). In contrast, three 14B10 Fabs 123 
and two NA9D7 Fabs target the virus capsid around its 3-fold and 2-fold axes, 124 
respectively, and thus up to 60 copies of 14B10 or NA9D7 Fabs can bind to each mature 125 
virion (Figures 2D and 2E). Because 18A7, 14B10 and NA9D7 bind to disparate loci, we 126 
further successfully obtained a quadruple immune complex (CVA16-127 
M:18A7:14B10:NA9D7) of  the CVA16 virion fully bound with each of the three Fabs 128 
(Figures S3J-S3I) and determined the cryo-EM structure at 3.67 Å. The density map 129 
confirms that the three Fabs can simultaneously bind to one mature virion without any 130 
steric hindrance (Figures 2F, S2L-S2N, S4I and Video S4). 131 
Interaction analysis of CVA16 immune complexes 132 
To elucidate the binding footprints of the three nAbs, we segmented out 10 asymmetric 133 
units of the quadruple immune-complex that reflected all the virion-Fab interacting 134 
scenarios (Figure 3A). Note that binding of one 18A7 Fab against 5 VP1 capsid proteins 135 
causes a symmetry mismatch in the arrangement of the 18A7 Fab with the capsid, such 136 
that regular icosahedral reconstruction results in an incomplete density of the 18A7 Fab 137 
at lower resolution (Figures 2A-2C). This is in contrast to the complete Fab densities of 138 
14B10 and NA9D7 (Figures 2D and 2E), which comply with the capsid symmetry. 139 
Similar symmetry mismatch has been observed in other Fab-capsid structure 140 
determinations, including EV71(Lee et al., 2013), human rhinovirus (HRV)(Hewat and 141 
Blaas, 2006), cucumber mosaic virus (CMV)(Bowman et al., 2002), and human 142 
papillomavirus (HPV)(Li et al., 2017); only partial density with these Fabs at a lower 143 
resolution can be resolved by the regular strategy. To overcome symmetry mismatch 144 
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and reveal high-resolution details of antibody-capsid interactions, we extracted the 12 5-145 
fold vertex regions of each CVA16-M:18A7 particle as sub-particles and subjected all 146 
sub-particles to 3D classification and refinement(Ilca et al., 2015). Five stable 3D classes 147 
emerged, each corresponding to binding of the 18A7 Fab at the 5-fold vertex in five 148 
orientations with 72° interval in one round. These five sub-particles share a similar 149 
occupancy ratio (7% to 12%) among the total sub-particle population (Figures 3B and 150 
S3), suggesting that the 18A7 Fab engages with each 5-fold vertex of the virion in a 151 
random manner, with a total of five possible orientations. Our highest resolution structure 152 
of the sub-particle is at 3.67 Å, which was obtained by refining sub-particles in class #5 153 
(CVA16-M:18A7-local) (Figures 3C, S3, S4J, Table 1 and Video S1). Based on this sub-154 
particle reconstruction and the above-described high-resolution structures of CVA16 with 155 
and without bound Fabs, we built atomic models for the Fab variable domains and the 156 
capsid although we excluded the constant domains for atomic modeling due to their 157 
structural flexibility (Figure S5).  158 
 Our asymmetric sub-particle reconstruction of the 18A7-CVA16 immune complex 159 
shows that 18A7 interacts, intriguingly, with all five VP1s at the 5-fold vertex region in the 160 
viral capsid, which buries a large surface area of ~1,184 Å2. 18A7 also interacts with all 161 
six of the complementarity-determining regions (CDRs) of the nAb (Table S1). The light 162 
chain accounts for ~69% of the buried surface area, and dominates the interaction 163 
through its involvement with all five VP1s, whereas the heavy chain accounts for ~31%, 164 
and interacts only with two VP1s (termed chain-B and chain-C) (Figures 3C, 3D and 165 
Table S1). The 18A7 neutralization sites cover the DE loop (K141-P148), the HI loop 166 
(E241-S246), and the BC loop (P96) of VP1, where residues V147, P148, P244, and 167 
H245 from three VP1s elaborately interact with the loops of the CDRs via numerous van 168 
der Waals contacts. In addition, P96 from the BC loop of chain-C targets Y54 of the CDR 169 
heavy chain loop 2 (H2) of 18A7 through a strong hydrogen bond (Figures 3D, 3E and 170 
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Table S1). Finally, we note that virus-escape mutants, generated under immune 171 
pressure from 18A7, bear a V147A mutation at the virus-antibody binding interface. 172 
Surface electrostatic potential analysis suggests that the interaction sites mostly 173 
comprise positively charged residues (Figure S6A) that associate with CVA16 binding to 174 
cellular receptors, such as heparan sulfate and human P-selectin glycoprotein ligand-1, 175 
putative receptors for enteroviruses (Figure S6B) (Nishimura et al., 2009; Zhang et al., 176 
2017). 177 
 Our structure of the 14B10-CVA16-M immune complex reveals that one 14B10 178 
Fab binds across every two adjacent protomer around the 3-fold region (Figures 3A and 179 
3F). The 14B10 Fab covers a buried surface area of ~761 Å2, of which the heavy chain 180 
accounts for ~56% (~425 Å2). The interaction sites include VP3 from one protomer 181 
(referred to as protomer 1, Figure 3F) and VP2 from the adjacent protomer (protomer 182 
10). Twelve hydrogen bonds, 7 salt bridges, and dozens of van der Waals contacts 183 
contribute to the interaction between 14B10 and the capsid. Of note, the donors of the 184 
available hydrogen bonds and salt bridges contributed by the VP2 protein of protomer 10 185 
are mediated mostly by the BC loop and the HI loop (Figures 3F, 3H, 3I and Table S1). 186 
Meanwhile, D74 of the BC loop of VP2, and S230 and E231 of the HI loop of VP2 make 187 
a number of interactions with 14B10, indicating that these are critical sites for 14B10 188 
neutralization (Figures 3H, 3I and Table S1). 189 
 Our structure of the NA9D7-CVA16 immune complex reveals that 60 copies of 190 
the NA9D7 Fab binds across two adjacent protomers at the 2-fold region (Figures 3A 191 
and 3G). The NA9D7 Fab has an interaction area of ~1200 Å2 across two protomers, of 192 
which ~69% (~824 Å2) is attributed to protomer 1 and ~31% (~376 Å2) to protomer 2. 193 
NA9D7 Fab extensively interacts with VP1, VP2, and VP3, specifically with the GH loop 194 
of VP1, the EF loop of VP2, and the GH loop of VP3 totaling 16 hydrogen bonds and 2 195 
salt bridges (Figures 3G, 3J, 3K and Table S1). Among these interactions, 12 bonds are 196 
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formed by each NA9D7 Fab binding to VP3 from its own protomer, whereas the other six 197 
bonds are donated from the adjacent protomer. Notably, L220 from VP1 and N143 from 198 
VP2 interact with multiple residues of Fab NA9D7 (Figures 3J, 3K and Table S1). CVA16 199 
escape mutants of NA9D7 harbor mutations in residue 220 of VP1 (L220V, L220S, or 200 
L220F), suggesting a critical role of L220 in the virus-antibody interaction. 201 
Structural analysis of neutralization sites for all three particle forms of CVA16 202 
To assess the three neutralization sites altered upon viral capsid transformation, we first 203 
determined the structures of the CVA16 mature virion, the A-particle and the empty 204 
particle at a resolution of 3.56 Å, 3.33 Å, and 3.43 Å, respectively (Figures 4A-4C, S4A-205 
S4C, and Table 1). We then compared the binding sites of the nAbs across the three 206 
particle forms. Of note, 14B10 and NA9D7 recognize neither the A-particle nor the empty 207 
particle. Our structures of the CVA16 mature virion and the A-particle are nearly identical 208 
to the corresponding virion and A-particle structures reported in other studies(Ren et al., 209 
2013; Ren et al., 2015) with RMSD values of 0.81 Å and 0.73 Å, respectively, for all of 210 
the Cα atoms of the VP proteins (Figures S7A and S7B). In contrast, the cryo-EM 211 
structure of the empty particle showed some conspicuous differences to that of the 212 
reported crystal structure (pdb code: 5C9A) (RMSD = 2.11 Å), which was derived from a 213 
sample that had been treated before crystallization with formaldehyde (Figure S7C) (Ren 214 
et al., 2015). Our cryo-EM structure of the A-particle is nearly identical to that of the 215 
empty particle (RMSD = 0.47 Å), with both demonstrating differences to the mature 216 
virion (RMSD = 2.38 Å and 1.87Å); these differences resulted from capsid 217 
transformation, including the collapsed pocket factor-binding regions, the expanded 2-218 
fold channels, and the lost VP4s (Figures S7D-S7F). Finally, superimpositions of the 219 
protomers of the viral particles with and without bound nAbs show neither global nor 220 
local conformational changes upon nAb binding (Figures S7G-S7K). 221 
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We next interrogated the structural variance of the three types of CVA16 particles 222 
that pivot on the 5-, 3- and 2-fold vertexes, respectively (Figures 4D-4F). Intriguingly, 223 
structural alignment of the viral vertex pivots of the mature virion and the A-particle 224 
(whose structure is nearly identical to that of the empty particle) showed almost identical 225 
5-fold and 3-fold channels, with only a 0.1° anti-clockwise rotation and a 0.5° clockwise 226 
rotation, respectively. Yet, there is significant variations for the 2-fold channel, with an 227 
anti-clockwise rotation of 1.7° (Figures 4D-4F). Most of the residues involved in the 228 
binding with 18A7 are related to the viral 5-fold channel and are located at the DE and HI 229 
loops of two VP1s (chain-B and chain-C). In addition, these residues show a highly 230 
similar conformation between the mature virion and the A-particle (RMSD = 0.36 Å) 231 
(Figure 4G). In contrast, the binding sites for 14B10 and NA9D7 nAbs in the mature 232 
virion are significantly different for the A-particle and the empty particle, with RMSD 233 
values of ~2.1 Å and ~4.8 Å, respectively (Figures 4H and 4I). Remarkably, the most 234 
deviated Cα atoms in the 14B10 epitope between the mature virion and the A-particle 235 
have a space shift of ~2.5 Å for K78 of VP3 and ~2.3 Å for S230-E231 of VP2 (Figure 236 
4H). However, in the NA9D7 binding region, the surface loops (VP1: GH loop, VP2: EF 237 
loop and VP3: GH loop) are flexible, with incontinuous densities for both the A-particle 238 
and the empty particle. Additionally, residues N108, D110, T275, and D292 of VP1, and 239 
N141 of VP3 in the mature virion move outward when transforming into the A-particle, 240 
reaching a maximal Cα shift ~4.3 Å (Figure 4I). Together, these results indicate that, 241 
besides the existence of shared antigenic sites (18A7 binding site) of all three types of 242 
particle forms, the mature virion structure possesses some unique epitopes and may 243 
serve as a more efficacious immunogenic vaccine candidate. 244 
Antibodies for identifying constituents of vaccine immunogens 245 
To explore sequence conservation and the underlying immune-dominance of the 246 
epitopes reciprocals to nAbs 18A7, 14B10 and NA9D7, we performed multiple sequence 247 
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alignments of VP genes from all the 157 virus strains of CVA16 in GenBank, and 248 
measured the blocking ratios of nAbs binding to full particle using native virus-infected 249 
human sera. As shown in the loop regions covering the three nAbs’ epitopes from the 16 250 
representative VP sequences, nAb 18A7 recognizes a discontinuous epitope spanning 251 
the DE loop and the HI loop of two adjacent VP1 capsid proteins (Figures 4G and 5A). 252 
Of note, 18A7 could not neutralize the 4479 strain when residues at positions 145 and 253 
241 of VP1 are glutamine and lysine, respectively; but are reactive with 190 strain with 254 
valine and glutamic acid at these positions. These results suggest that the 18A7 epitope 255 
is less sequence conserved among native virus isolates, despite that it holds integrity 256 
across the three capsid forms of the 18A7-reactive viruses. In contrast, 14B10 and 257 
NA9D7 can neutralize all four of the tested CVA16 strains and have highly conserved 258 
(~99% and ~97%, respectively) strategic epitope residues across all of the aligned 157 259 
CVA16 strains (Figure 5A).  260 
Naturally acquired anti-CVA16 human sera could block nAbs 18A7, 14B10, and 261 
NA9D7 from binding to the CVA16 full particles at blocking rates of 12.4%, 14.8%, and 262 
60%, respectively. This shows that NA9D7, but not 18A7 or 14B10, likely binds a 263 
dominant, immunogenic site of CVA16. The NA9D7 site thus may serve as a major 264 
target for an effective vaccine constituent that solely exists at the mature virion and may 265 
disrupt transformation to A-particles and empty particles (Figure 5B). It is worth 266 
mentioning that the presence of murine NA9D7 could not directly reflect on the antibody 267 
generation in human albeit it partially competes the binding of the CVA16 reactive 268 
human sera in competition ELISA. It would be necessary to explore whether the 269 
category of NA9D7-like antibody could be dominantly elicited in human upon the native 270 
infection of CVA16 virus. 271 
We next verified the unique epitopes in the mature virions by evaluating antibody 272 
responses after vaccination with purified CVA16 (190 strain) full particles and empty 273 
13 | P a g e  
 
particles in mice. As expected, full particles elicited 1.83- to 2.14-times higher 274 
neutralizing antibody titers than those of the empty particles for all four virus strains (P < 275 
0.001). The neutralization titers from the full particles of the CVA16 190 strain was 28.8, 276 
and cross-neutralization against the 213a, 4430, and 4479 strains was achieved at 210.0, 277 
210.8, and 29.0, respectively; all of these values surpass the putative protection level of a 278 
neutralization antibody titer suggested in previous studies (Figure 5C)(Cai et al., 2013; 279 
Chong et al., 2012). Taken together, we conclude that the CVA16 mature virion harbors 280 
the predominant immunogenic site, at least in the region around the 2-fold axis of the 281 
intact virion, where it accommodates a 2-fold channel that is open during capsid 282 
transformation and associated with genome release(Ren et al., 2013; Wang et al., 283 
2012). Thus, virus strain(s) bearing the conserved neutralization epitope(s) and 284 
possessing a maximum proportion of the mature virion during cell culture may be 285 
selected as a candidate(s) for CVA16 vaccine development. 286 
Given that these three nAbs provide distinctive indicators when neutralization is 287 
achieved, we next designed two double-antibody sandwich ELISA assays to monitor 288 
particle proportion and mature virion stability during CVA16 immunogen production. In 289 
the first ELISA assay, 18A7, which was expected to bind/capture all virus particle forms, 290 
hereafter referred to as the “capture antibody,” was immobilized to the microplate. For 291 
the second, we used NA9D7 as the capture antibody to exclusively harvest the mature 292 
virions in the sample. Then, for both assays, 18A7 was labeled with secondary antibody 293 
to horseradish peroxidase (HRP), termed 18A7-HRP, and used as the detection 294 
antibody. The EC50 values, which are calculated from curves of OD vs. the input particle 295 
concentration, showed comparable reactivities for the full particles, the empty particles, 296 
and their mixture (v:v=1:1) in the 18A7/18A7-HRP ELISA, but read 3.45, 9.33 and 4.49 297 
μg/mL for these three samples respectively, indicative of differences in the abundance of 298 
mature virions in these samples (Figures 5D-5F). A correlation of the mature virions and 299 
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the plenary particles using these two ELISAs can thus be used to quantify the effective 300 
constituents of vaccine immunogens and their stability during vaccine development. 301 
Discussion 302 
High-resolution structures of viruses and their immune complexes provide valuable 303 
information for vaccine discovery and design. For pathogens such as HIV-1, RSV, and 304 
influenza, the neutralizing antibodies elicited by vaccines act almost exclusively through 305 
one or two enveloped glycoproteins or specific sites with conformational 306 
integrity(Laursen et al., 2018; McLellan et al., 2013; Xu et al., 2018). Thus, immunogen 307 
screening using conformation as a basis is essential for effective vaccine development. 308 
However, the enterovirus life cycle—encompassing the transformation of procapsids, 309 
mature virions, A-particles and empty particles—means that different components, 310 
structures, and immunogenicity can exist and thereby influence the utility of a vaccine, 311 
depending on the stage of the life cycle during treatment(Baggen et al., 2018; Shingler et 312 
al., 2013). The poliovirus D-antigen expressed on the mature virion is an important 313 
determinant of antigenicity and immunogenicity, owing to the regnant and integrated 314 
neutralizing epitopes; this contrasts with the C-antigen on A-particles and empty 315 
particles, which are known to generate poor immunogenic responses to viral 316 
infection(Ferguson et al., 1993). Similar to other studies(Chong et al., 2012), we show in 317 
the current study that the mature virions of the full particles of CVA16 induce higher 318 
neutralizing antibody titers than the other particle types, possibly due to their expression 319 
of protected antigenic sites. Our neutralizing antibodies, together with structural 320 
information of their interaction, further clarified the mature virion-specific neutralizing 321 
epitopes of 14B10 and NA9D7 nAbs. We show that both epitopes are highly conserved 322 
in most CVA16 strains, with the NA9D7 epitope being an immunodominant antigenic site 323 
(Figures 5A-5C), however, the antibody was produced in mice by the immunization of 324 
CVA16 cell culture, whether it reflects a similar situation in the antibody reservoir of a 325 
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virus-infected human should be further interrogated. Collectively, these findings suggest 326 
that the mature virion of CVA16 should be targeted for vaccine design, and at least the 327 
structural integrity of NA9D7-like epitope that exclusively remains in mature virion should 328 
be well-characterized and rationally introduced to the vaccine immunogen. Our findings 329 
of three distinctive nAbs call for an approach of sandwiching ELISA of 18A7:18A7-HRP 330 
and 18A7:NA9D7-HRP) to quantify the proportion of mature virions present in vaccine 331 
preparation (Figures 5D-5F).  332 
Previous structural studies have depicted how picornaviruses attach and gain 333 
entry into the cell(Hogle et al., 1985; Ren et al., 2013; Wang et al., 2012; Zheng et al., 334 
2019). Entry of the mature virion is initiated through receptor-mediated binding, which 335 
initiates endocytosis and triggers the formation of a cell-entry intermediate or an A-336 
particle(Baggen et al., 2018; Bergelson and Coyne, 2013; Johnson, 2010). 337 
Neutralization can occur at multiple steps of the infection process. For picornavirus 338 
EV71, EV-D68, and HRV, nAbs can cross-react with different conformational states near 339 
the icosahedral 3-fold axis, and thereby promote the untimely uncoating of the virus and 340 
its genome release(Dong et al., 2017; Plevka et al., 2014; Zheng et al., 2019). Here, 341 
using biochemical and structural analyses, we show that 14B10 and NA9D7 nAbs 342 
cannot bind to the A-particle or empty particle only the mature virion (Figures S1B, S1C, 343 
S2G and S2J). Furthermore, the nAbs’ binding either in Fab or full-length antibody form 344 
can stabilize the full particles as manifested by 1.0-2.5 °C higher melting temperature 345 
than unbound full particles in fluorescence-based thermal stability assays (Figures 1D-346 
1F), exceptionally, 14B10 Fab can even stabilize by 10°C, much higher than 14B10 full-347 
length antibody (1.8 °C), the discrepancy might arise from only ⅓ 14B10 binding sites 348 
coordinated around 3-fold axis being occupied with full-length antibodies due to the 349 
steric hindrance (Figures S6C and S6E). Taken together with the structural information 350 
of all three Fabs binding to the virus across two or more protomers (Figures 3D, 3F and 351 
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3G), we demonstrate the three nAbs may neutralize CVA16 by restricting the 352 
conformational changes of the mature virion, such changes that are vital for viral entry 353 
and RNA release. As for the potential for full-length antibody bivalently interacting with 354 
the capsid, we fitted multiple full-length antibody models (PDB no. 1IGY) (Harris et al., 355 
1998) to representative Fab densities within the cryo-EM structures of the immune 356 
complexes CVA16-M:14B10 and CVA16-M:NA9D7. The fitted models showed that two 357 
full-length antibodies of either 14B10 or NA9D7 are impossible to bivalently interact with 358 
two adjacent regions coordinated with 3-fold or 2-fold axis (Figures. S6C, S6D, S6F and 359 
S6G), even the hinge linking two Fabs in the full-length antibody is highly flexible. 360 
NAbs of picornaviruses commonly target the exposed loop regions of the viral 361 
capsid, some of which overlap with the viral receptor binding sites. Although several 362 
receptors have been identified for many picornaviruses(Nishimura et al., 2009; 363 
Yamayoshi et al., 2009), the binding structural details of the CVA16 receptor is still 364 
poorly understood. However, the binding sites of other virus types have been outlined 365 
and lend important structural insight. For instance, the poliovirus and rhinovirus 366 
receptors on the viral surface cover the BC and HI loops on VP1 around the 5-fold 367 
icosahedral vertices of the capsid(Belnap et al., 2000; Hewat et al., 2000; Xing et al., 368 
2000). In addition, studies have shown that EV71 and CVA16 use SCARB2 and PSGL-1 369 
as functional receptors for cell entry, with the binding site of the EV71 SCARB2 receptor 370 
on the southern rim of the canyon of the VP1 GH and VP2 EF loops (Figure S6B)(Zhou 371 
et al., 2019). Here, we show that the neutralization epitope of 14B10 is located on the 372 
VP3 BC loop and the VP2 BC, EF, and HI loops at the 3-fold vertex. In contrast, we 373 
show that NA9D7 mainly targets the VP1 GH and VP2 EF loops surrounding the 2-fold 374 
axis (Figures 3F, 3G and S6B). These findings suggest that these loops may be involved 375 
in SCARB2 receptor binding, and function in CVA16 attachment to the cell surface. In 376 
addition, the footprint of 18A7 covers the DE and HI loops of VP1 at the 5-fold vertex, 377 
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where it associates with CVA16 binding to other identified receptors, PSGL-1 and 378 
heparan sulfate (HS) (Figure 3D and S6B)(Nishimura et al., 2009; Zhang et al., 2017). 379 
Thus, the structural atlas of the three nAbs may help to identify the receptor binding site 380 
for CVA16. 381 
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Main figure titles and legends 407 
 408 
Figure 1. Characterization of anti-CVA16 NAbs 18A7, 14B10, and NA9D7. 409 
(A and B) Cross-neutralizing efficacy of 18A7 (A) and 14B10 (B) against CVA16 strains 410 
190, 213a, 4430, and 4479 were evaluated using an in vitro micro-neutralization assay in 411 
human rhabdomyosarcoma (RD) cells. The neutralization efficacy was evaluated using 412 
the IC50 values calculated from the inhibition ratio plotted against antibody concentration. 413 
(C) In vivo protective efficacies of antibodies against CVA16. One-day-old mice were 414 
challenged with CVA16 and then treated with 18A7, 14B10, or NA9D7 after virus 415 
infection. The control group were treated with PBS. Mouse survival rates were monitored 416 
and recorded daily for 20 days. 417 
(D-F) Stabilities of CVA16 full particles and their immune complexes with 18A7 (D), 418 
14B10 (E), or NA9D7 (F) determined by thermal stability assays using the SYTO9 dye to 419 
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detect RNA exposure. The first derivatives are shown and the experiments were 420 
independently repeated in triplicates. 421 
See also Figure S1. 422 
 423 
Figure 2. cryo-EM structures of immune complexes of CVA16-M:18A7, CVA16-424 
A:18A7, CVA16-E:18A7, CVA16-M:14B10, CVA16-M:NA9D7 and CVA16-M: 425 
18A7:14B10:NA9D7. 426 
(A-F) Radially colored surface views down a two-fold axis of the cryo-EM density maps 427 
of the immune complexes CVA16-M:18A7 (A), CVA16-A:18A7 (B), CVA16-E:18A7 (C), 428 
CVA16-M:14B10 (D), CVA16-M:NA9D7 (E) and CVA16-M:18A7:14B10:NA9D7 (F). Fabs 429 
18A7, 14B10, and NA9D7 bind the capsid around its 5-, 3- and 2-fold axes, respectively. 430 
These axes are denoted by the corresponding numbers with the triangle demarking an 431 
asymmetric unit. 432 
See also Figures S2-S5 and Table 1 and Videos S1-S4. 433 
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 434 Figure 3. Sub-particle reconstruction of the CVA16-M:18A7 immune complex and 435 
interaction analysis of CVA16-M:18A7, CVA16-M:14B10, and CVA16-M:NA9D7.  436 
(A) Surface view of the cryo-EM densities of two adjacent five-fold vertexes of CVA16-437 
M:18A7:14B10:NA9D7, containing 10 asymmetric units. Fabs bound to these ten 438 
asymmetric units include two 18A7 Fabs (orange), 10 14B10 (heavy chain: cyan, light 439 
chain: cyan) and 10 NA9D7 (heavy chain: magenta, light chain: red). Icosahedral 2-, 3-, 440 
and 5-fold axes are indicated by black ellipse, triangle, and pentagon symbols, 441 
respectively. 442 
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(B) Sub-particle reconstruction of the CVA16-M:18A7 five-fold vertex yielded five well-443 
defined 3D classes from different number of sub-particles (percentages indicated) 444 
showing different Fab binding directions. 445 
(C and D) Surface views of the final sub-particle reconstruction of the five-fold vertex 446 
showing CVA16-M:18A7 binding (resolution 3.67 Å) viewed from side (C) and top (D). In 447 
d, the Fab density is removed to reveal the footprint of Fab 18A7 on a surface area 448 
buried by the Fab heavy (gold) and light (orange) chains. 449 
(E) Close-up of the interface between the capsid and Fab 18A7 with residues 450 
participating in the interactions labeled and their side chains shown as sticks on the 451 
ribbon models. 452 
(F and G) Footprints of Fabs 14B10 (F) and NA9D7 (G) on the CVA16 viral capsid 453 
rendered as surface representation. 454 
(H and I) Close-up views of the interface between the capsid and either the heavy (H) or 455 
the light chain (I) of Fab 14B10. 456 
(J and K) Fab NA9D7 interacts with the GH loop of VP1 (J), the EF loop of VP2, and the 457 
GH loop of VP3 (K). Hydrogen bonds and salt bridges are marked by yellow dashed 458 
lines. Side chains involved in the interaction between the antigen and the antibody are 459 
labeled and shown as sticks. Asterisks mark the position of an escape mutation. 460 
Proteins are colored according to the codes at the bottom. 461 
See also Figures S3 and S6 and Table S1. 462 
23 | P a g e  
 
 463 
Figure 4. Structural and antigenic comparisons among different types of CVA16 464 
particles. 465 
(A-C) Radially colored surface views of the cryo-EM density maps of the CVA16 mature 466 
virion (A), A-particle (B) and empty particle (C). 467 
(D-F) Structural comparisons of the mature virion and A-particle (which is highly similar 468 
to the empty particle) on their viral 5-fold (D), 3-fold (E) and 2-fold (F) vertexes, 469 
respectively. The variable regions of one 18A7 Fab (heavy chain: orange, light chain: 470 
yellow), three 14B10 Fabs (heavy chain: cyan, light chain: light blue) and two NA9D7 471 
Fabs (heavy chain: magenta, light chain: pink) bound to the viral 5-fold (D), 3-fold (E) 472 
and 2-fold (F) vertexes are shown as surfaces. Diagrams in the upper-right corner depict 473 
the structural discrepancy for different protomers located in 5-fold, 3-fold, or 2-fold 474 
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vertexes, with global rotation against the corresponding icosahedral axes between the 475 
mature virion (colored) and the A-particle (gray, 50% transparency). The axes are 476 
located at the center of the diagrams and are perpendicular to the page. 477 
(G-I) Close-up views and structural comparisons of the binding sites of 18A7 (G), 14B10 478 
(H), and NA9D7 (I) between the mature virion and the A-particle. The 18A7 binding sites 479 
cover five VP1s localized to the 5-fold vertex of the viral capsid (blue) (G). (H) Important 480 
differences in the residues between the mature virion and A-particle (rectangle). (I) 481 
NA9D7 epitope residues of the mature virion that were not interpreted in the A-particle 482 
model are boxed in the dashed rectangle. VP1, VP2, VP3, and VP4 of the CVA16 483 
mature virion are colored blue, green, red, and yellow, respectively. The A-particle model 484 
is in gray. The amino acid residues of CVA16 involved in nAb-capsid interactions in (G-I) 485 
are shown as sticks. 486 
See also Figure S7. 487 
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 488 
Figure 5. Conservation analysis of neutralization epitopes and ELISA of purified 489 
CVA16 particles. 490 
(A) Sequence alignment showing the epitopes of the three Fabs covering 16 strains of 491 
CVA16. The neutralization epitopes are boxed as cream (18A7), purple (14B10) and pink 492 
(NA9D7), respectively. The amino acid residue conservation is depicted beneath the 493 
boxes using the Weblogo representation of the alignment of 157 CVA16 strains. 494 
(B) Competitive ELISA of 18A7, 14B10, and NA9D7. Antibodies were conjugated to HRP 495 
and then used to block the binding of CVA16-positive human sera to CVA16 particles 496 
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that were pre-coated on ELISA plates. The percentage of blockage is expressed as the 497 
mean ± standard deviation (SD). 498 
(C) Cross-strain in vitro neutralizing efficacies of antisera elicited by different types of 499 
CVA16 particles. BALB/c mice were vaccinated intraperitoneally with CVA16 strain 190 500 
full particles or empty particles. The neutralizing efficacies of the antisera collected from 501 
mice against CVA16 strains 190, 213a, 4430, and 4479 were evaluated by neutralization 502 
assay, with neutralizing titers expressed as mean ± SD. Statistical significance was 503 
analyzed by an unpaired Student’s t-test (***P < 0.001).  504 
(D-F) Reactivities of CVA16 particles by two modes of double-antibody sandwich 505 
ELISAs. The ELISA systems used 18A7 paired with 18A7-HRP or 18A7 paired with 506 
NA9D7-HRP as the capture and detection antibody for the detection of plenary particles 507 
and mature virions, respectively. CVA16 full particle (D), empty particle (E) and 1:1 508 
mixture (F) were tested in the two ELISA systems. EC50 values were calculated with 509 
curves generated by nonlinear regression fitted. 510 
 511 
Main table titles 512 
Table 1. Cryo-EM data collection, refinement and validation statistics.  513 
The Table shows cryo-EM data collection, reconstruction, and model validation results 514 
and values. See also Figures S2-S4. 515 
  516 
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STAR☆METHODS 517 
Detailed methods are provided in the online version of this paper and include the following: 518 
 KEY RESOURCES TABLE 519 
 CONTACT FOR REAGENT AND RESOUREC SHARING 520 
 EXPERIMENTAL MODEL AND SUBJECT DETAILS 521 
 Mice 522 
 Cell lines and viruses 523 
 METHOD DETAILS 524 
 QUANTIFICATION AND STATISTICAL ANALYSIS 525 
 DATA AND SOFTWARE AVAILABILITY 526 
 Data Resources 527 
CONTACT FOR REAGENT AND RESOURCES SHARING 528 
Further information and requests for resources and reagents should be directed to and 529 
will be fulfilled by the Lead Contact, Ning-Shao Xia (nsxia@xmu.edu.cn). 530 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 531 
Mice 532 
BALB/c mice were obtained from the Slac Laboratory Animal Co., Shanghai, China. All 533 
mice were maintained in a specific-pathogen-free facility of Xiamen University. For 534 
infection studies, mice were maintained in BSL2 facility under the following housing 535 
conditions. The mice were housed in a temperature-controlled (20-25 °C), air-536 
conditioned room on a 12-hr light-dark cycle, and supplied with corn cob bedding (1/4-537 
inch depth), irradiated diet and sterilized water. All animal experimental protocols were 538 
approved by the Xiamen University Laboratory Animal Center (XMULAC) and were 539 
conducted in strict compliance with the guidelines of the Xiamen University Institutional 540 
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Committee for Care and Use of Laboratory Animals (approval code: 541 
XMULAC20160049). 542 
Cell lines and viruses 543 
Human rhabdomyosarcoma (RD) cells were obtained from the American Type Culture 544 
Collection (ATCC, CCL-136) and maintained in minimal essential medium (MEM, Gibco) 545 
supplemented with 10% fetal bovine serum (FBS, Gibco). The CVA16/190 strain 546 
(GenBank accession no. KJ850274) was isolated from an HFMD clinical specimen in 547 
Taiwan. The CVA16/213a strain (GenBank accession no. JX127259), the CVA16/4430 548 
strain (GenBank accession no. JX127274) and the CVA16/4479 strain (GenBank 549 
accession no. JX127277) were isolated from HFMD clinical specimens in Fujian. The 550 
CVA16/190 strain was used for all biochemical and structural analyses. The 551 
CVA16/213a, 4430, and 4479 strains were used only in the in vitro neutralization assay. 552 
Viruses were stored in aliquots at −80°C in our laboratory.  553 
METHODS DETAILS 554 
Virus production and purification 555 
CVA16 was grown in RD cells at a multiplicity of infection (MOI) of 0.2 at 37°C for 3 556 
days. After infection, the virus was centrifuged to remove cell debris at 6,000 ×g for 30 557 
min and precipitated using 7% (w/v) polyethylene glycol (PEG) 6,000 and 0.3 M NaCl in 558 
PBS at 4°C overnight. After centrifugation, the virus was resuspended in PBS and then 559 
loaded onto a linear 15% to 45% (w/v) sucrose density gradient in a Beckman SW41 Ti 560 
rotor at 135,000 ×g for 4 h. Virus fractions were independently collected and dialyzed 561 
against PBS, and further concentrated by an Ultra-4 centrifugal concentrator. The 562 
quantity and quality of CVA16 particles were assessed by negative-staining electron 563 
microscopy. 564 
Preparation of antibodies and antibody fragments 565 
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To obtain mAbs 18A7, 14B10, and NA9D7, BALB/c mice were immunized 566 
subcutaneously with the supernatant of CVA16 cultures emulsified in Freund’s adjuvant 567 
and boosted twice at 2-week intervals. After the final boost, splenic cells from immunized 568 
mice were fused with myeloma cells (Sp2/0) and the hybridoma supernatants were 569 
screened using a neutralization assay against CVA16. Antibodies were purified from 570 
mouse ascites fluid using protein A affinity columns. The sequences of the variable 571 
regions of the heavy and light chains of the antibodies were determined by cloning and 572 
sequencing. To obtain antibody Fab fragments, mAbs were digested with 10/00 (w/w) 573 
papain in 20 mM PB (pH 7.0) containing 30 mM L-Cys and 50 mM EDTA at 37°C for 12 574 
h. The resulting Fab fragments were separated from the Fc fragments using a DEAE 575 
column. 576 
In vitro neutralization assay 577 
RD cells were pre-seeded into 96-well plates at 2 × 104 cells per well. Antibodies or 578 
antisera collected from mice were serially diluted 2-fold and incubated with an equal 579 
volume of CVA16 (104 TCID50 per well) at 37°C for 1 h. Each mixture was then added to 580 
cells and incubated at 37°C for 24 h. After incubation, an enzyme-linked immunosorbent 581 
spot (Elispot) assay was performed(Hou et al., 2015). The inhibition rate of the antibody 582 
was calculated using the following formula: Neutralization % = (1-[Ntest - Ncell control]) / 583 
(Nvirus control -Ncell control) × 100%. In this formula, Ntest, Ncell control and Nvirus control are the 584 
average number of spots in the test wells, cell control wells, and virus control wells, 585 
respectively. The IC50 was calculated from nonlinear regression fitting curves using 586 
GraphPad Prism version 7.0. The neutralization titers were defined as the highest 587 
dilution giving >50% neutralization. The experiments were performed in triplicate. 588 
In vivo protection assay 589 
Groups of 1-day-old mice (n = 8) were challenged intracranially (i.c.) with 105 TCID50 590 
CVA16 at 24 h before intraperitoneal (i.p.) infection with antibodies. The mice in the 591 
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control group were treated with PBS buffer. All mice were monitored and recorded daily 592 
until 20 days’ post-infection. 593 
Particle stability thermal release assay 594 
A ThermoFluor assay(Walter et al., 2012) was performed with an MX3005P RT-PCR 595 
instrument (Agilent). The presence of RNA was detected with an environment-sensitive 596 
fluorescent dye, SYTO9 (Invitrogen). Each 50-μl reaction mixture was prepared in thin-597 
walled PCR plates (Agilent), containing 1 μg of CVA16 full particles and 5 μM SYTO9 in 598 
PBS buffer. The fluorescence level was recorded in triplicate at 0.5°C intervals from 599 
25°C to 99°C.  600 
Generation and sequencing of the escape mutant viruses 601 
For the first round of infection, antibodies (0.2 mg/ml) were incubated with 106 TCID50 of 602 
CVA16 at room temperature for 1 h and then at 37°C for 2 h. The mixtures were added 603 
to RD cells and incubated at 37°C until cytopathic effect (CPE) developed. The cultures 604 
were harvested and subjected to three freeze-thaw cycles, and then clarified by 605 
centrifugation. For the second and third rounds of infection, the antibody concentration 606 
was increased to 0.8 mg/ml. After selection, the resultant resistant viruses were purified 607 
from plaques and cloned into RD cells. The P1 region of the viral genome was amplified 608 
by RT-PCR using primers (forward 5’ -TTAAAACAGCCTGTGGGT- 3’ and reverse 5’ -609 
CGTTGTTATCTTGTCTCTACTAGT-3’) and verified by DNA sequencing. 610 
Vaccine preparation and immunization of mice 611 
The immunogenicity of the CVA16 virus was evaluated in 6-week-old female BALB/c 612 
mice. Purified CVA16 full particles and empty particles were diluted in PBS with an equal 613 
volume of aluminum adjuvant. Groups of mice (n = 5 per group) were respectively 614 
vaccinated with CVA16 full particles, CVA16 empty particles, or aluminum adjuvant 615 
(control) at days 0 and 21. Each mouse was intraperitoneally immunized with 1.5 μg per 616 
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dose in 0.5-ml samples. Antisera were inactivated by incubation at 56°C for 30 min and 617 
stored at −20°C for in vitro neutralization assays. 618 
Binding ELISA 619 
ELISA plates were pre-coated with the purified CVA16 full particles or empty particles at 620 
50 ng per well at 4°C overnight and blocked with 5% skim milk in PBS at 37°C for 2 h. 621 
Antibodies were added into the wells at various concentrations and incubated at 37°C for 622 
1 h. Each well was then incubated with horseradish peroxidase (HRP)-conjugated goat 623 
anti-mouse (GAM-HRP; 1:5000 dilution) IgG antibodies at 37°C for 30 min. For color 624 
development, the plates were incubated with a TMB chromogen substrate solution at 625 
37°C for 15 min, and the reaction was terminated with 2 M H2SO4. The absorbance was 626 
measured at A450/620. 627 
Competitive ELISA 628 
CVA16-positive human sera (1:100 dilution) were added into wells pre-coated with the 629 
purified CVA16 full particles at 37°C for 30 min. The HRP-conjugated mAbs 18A7, 630 
14B10, or NA9D7 were then added respectively. After 30 min of incubation at 37°C, the 631 
plates were subjected to color development as described for the Binding ELISA 632 
(Methods). The absorbance was measured at A450/620. Percentage inhibition (PI) was 633 
calculated as: PI (%) = 100 – [(ODsample/ ODcontrol) × 100]. 634 
Sandwich ELISA 635 
Samples of CVA16 (1) full particles + empty particles (1:1 mass), (2) full particles, or (3) 636 
empty particles were diluted in PBS in 5-fold serial dilutions, and then added to wells 637 
pre-coated with mAb NA9D7 or 18A7 (200 ng per well) and incubated at 37°C for 1 h. 638 
The HRP-conjugated mAb 18A7 was used as the detecting antibody (1:2,000 dilution). 639 
After 30 min at 37°C, the plates were subjected to color development, as described for 640 
the Binding ELISA (Methods). Absorbance was measured at A450/620. 641 
Cryo-EM sample preparation and data collection 642 
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Purified 18A7, 14B10, or NA9D7 Fab fragments were incubated with CVA16 full particle 643 
at room temperature for 30 min at a molecular ratio of 72 Fab per viral particle. For the 644 
quadruple immune complex (CVA16-M:18A7:14B10:NA9D7), three Fabs were 645 
simultaneously mixed with the CVA16 full particle using the same ratio as above. A 3-μl 646 
aliquot of purified full particle, empty particle or immune complex was applied to freshly 647 
glow-discharged holey carbon Quantifoil Cu grids (R2/2, 200 mesh, Quantifoil Micro 648 
Tools) and then blotted for 6 s before plunge-freezing the grids into liquid ethane cooled 649 
by liquid nitrogen inside a Vitrobot Mark IV (Thermo Fisher Scientific) at nearly 100% 650 
humidity and 8°C. The cryo-grids were initially checked at 300 kV with the FEI Tecnai 651 
F30, with only good quality grids selected for data collection. Cryo-EM images acquired 652 
with the FEI Titan Kiros (Thermo Fisher Scientific) EM were recorded on a Gatan K2 653 
Summit direct electron detector at a nominal 130,000× magnification, corresponding to a 654 
calibrated physical pixel size of 1.307 Å (0.6535 Å for super-resolution pixel size). 655 
Movies comprise 40 frames, with a total dose of 56 e-/Å2 at an exposure time of 8 s. 656 
Data were semi-automatically collected using SerialEM(Mastronarde, 2003). Cryo-EM 657 
images acquired with the FEI Tecnai F30 were recorded on the Falcon II or III direct 658 
electron detector at a nominal 93,000× magnification, corresponding to a pixel size of 659 
1.128 Å or 1.120 Å, respectively. A total electron dose of about 40 e-/Å2 was fractionated 660 
into 17 or 39 frames in every movie at an exposure time of 1 s. Data were automatically 661 
collected using FEI EPU. 662 
Three-dimensional reconstruction 663 
Drift and beam-induced motion correction were performed with MotionCor2(Zheng et al., 664 
2017). Contrast transfer function (CTF) fitting and phase-shift estimation were carried 665 
out with Gctf(Zhang, 2016). Micrographs with astigmatism, significant drift, or 666 
contamination were discarded before reconstruction. Particles were automatically picked 667 
and screened using cisTEM(Grant et al., 2018). The initial 3D models for each dataset 668 
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were generated with a random model method using AUTO3DEM(Yan et al., 2007). 669 
Several rounds of reference-free 2D classifications and unsupervised 3D classifications 670 
were executed using Relion 2.1(Kimanius et al., 2016). Sorted particles were then 671 
subjected to final homogenous refinement using Relion 2.1, cisTEM, or cryoSPARC 672 
v2.4.2(Punjani et al., 2017). The resolution of all density maps was determined by the 673 
gold-standard Fourier shell correlation curve with a cutoff at 0.143. Local map resolution 674 
was estimated with ResMap(Kucukelbir et al., 2014). 675 
Sub-particle classification and refinement for CVA16-M:18A7 676 
To resolve the structures of 18A7 Fab at high resolution, we used Relion symmetry 677 
expansion and Scipion(De la Rosa-Trevín et al., 2016) to exact and perform sub-particle 678 
reconstruction as previously described(Ilca et al., 2015). Briefly, after 3D refinement with 679 
imposition of icosahedral symmetry, we extracted sub-particles from the 5-fold region in 680 
a box-size of 140×140 pixels and expanded the sub-particles with I2 symmetry. The 681 
extracted sub-particles were used to generate the initial model using relion_reconstruct. 682 
3D classification was then performed without alignment. Five classes (#1, #5, #6, #7, #8) 683 
revealed distinguished features of the Fab fragment, of which class #5 reconstruction 684 
had the highest quality. Further refinement of class #5 led to a structure at 3.67 Å 685 
resolution. The resolution was assessed by Fourier shell correlation curve with a cutoff 686 
at 0.143 from two independent half-sets of the sub-particles. The work flow is depicted in 687 
Figure S5. 688 
Model building and refinement 689 
As the constant domain of the Fab fragment exhibited very weak densities, we only built 690 
the variable domain model for structural analysis (Figure S8). The initial atomic models 691 
for the variable domain of the Fab fragments (18A7, 14B10 and NA9D7) were generated 692 
from homology modeling by Accelrys Discovery Studio software(Studio, 2009). 693 
Combining with the crystal structures of the CVA16 mature virus (pdb code: 5C4W), A 694 
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particle (pdb code: 4JGY), and empty particle (pdb code: 5C9A), we initially fitted the 695 
templates into the corresponding segmented volume (enclosing a protomer) of the final 696 
cryoEM maps (viral particles or immune complexes) using Chimera(Pettersen et al., 697 
2004) and further corrected and adjusted manually by real-space refinement in 698 
Coot(Emsley and Cowtan, 2004). The built models were then refined using 699 
phenix.real_space_refine in PHENIX(Adams et al., 2010). These operations were 700 
executed iteratively until the problematic regions, Ramachandran outliers, and poor 701 
rotamers were in favor. After several cycles of refinement, the resulting models were 702 
fitted into the map of six neighboring protomers. These total of seven protomers were 703 
taken together for further refinement to optimize the clashes. The final atomic models 704 
were validated using Molprobity(Chen et al., 2010). Model statistics are summarized in 705 
the Extended Data Table 1. Sequence alignment was performed with Clustal Omega on 706 
the EBI server (https://www.ebi.ac.uk/Tools/msa/clustalo/). The Fab-capsid buried 707 
surface area and interaction interfaces were calculated using the CCP4(Collaborative, 708 
1994) program suite and the PISA server (www.ebi.ac.uk/pdbe/pisa). For the 709 
intermolecular interactions, maximal cut-off distances of 4.0 Å were used for hydrogen 710 
bonding, salt-bridge formation and other contacts. The roadmap in graphical abstract 711 
was generated using Rivem(Xiao and Rossmann, 2007). All figures were generated with 712 
ChimeraX(Goddard et al., 2018), Chimera, or Pymol(Schrodinger, 2010). 713 
QUANTIFICATION AND STATISTICAL ANALYSIS 714 
Statistical significance was determined as p < 0.05 using GraphPad Prism 7.0. Data 715 
were analyzed by unpaired Student’s t-test analysis. 716 
DATA AND SOFTWARE AVAILABILITY 717 
Data Resources 718 
The cryo-EM density maps and corresponding atomic coordinates have been deposited 719 
in the Electron Microscopy Data Bank (EMDB) and Protein Data Bank (PDB), 720 
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respectively. The accession codes are: CVA16 mature virion (EMD-0887, PDB: 6LHA); 721 
CVA16 A-particle (EMD-0888, PDB: 6LHB); CVA16 empty particle (EMD-0889, PDB: 722 
6LHC); CVA16-M:18A7(EMD-0890, PDB: 6LHK); CVA16-M:18A7-local (EMD-0897, 723 
PDB: 6LHT); CVA16-A:18A7 (EMD-0891, PDB: 6LHL); CVA16-E:18A7 (EMD-0892, 724 
PDB: 6LHO); CVA16-M:14B10 (EMD-0894, PDB: 6LHP); CVA16-M:NA9D7 (EMD-0895, 725 
PDB: 6LHQ); CVA16-M:18A7:14B10:NA9D7 (EMD-0898).  726 
  727 
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Supplemental table 728 
Table S1. Interactions between different Fabs and CVA16 mature virion, Related to 729 
Figure 3. 730 
 731 
Supplemental movie 732 
Video S1. Overall structure and high-resolution features of CVA16-M:18A7 733 
immune complex, Related to Figures 2 and 3. 734 
Depicts the global reconstructed features of CVA16-M:18A7 at the level of 1.5σ and 3.5735 
σ. The 3.67 Å high-resolution features of CVA16-M:18A7-local was shown. 736 
Video S2. Overall structure of CVA16-M:14B10 immune complex, Related to Figure 737 
2.  738 
Depicts the global reconstructed features of CVA16-M:14B10, and close-up view of the 739 
14B10 binding region. 740 
Video S3. Overall structure of CVA16-M:NA9D7 immune complex, Related to 741 
Figure 2.  742 
Depicts the global reconstructed features of CVA16-M:NA9D7, and close-up view of the 743 
9D7 binding region. 744 
Video S4. Overall structure of CVA16-M:18A7:14B10:NA9D7 immune complex, 745 
Related to Figure 2.  746 
Depicts the global reconstructed features of CVA16-M: 18A7:14B10:NA9D7 747 
  748 
37 | P a g e  
 
References 749 
Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., 750 
Hung, L.-W., Kapral, G.J., and Grosse-Kunstleve, R.W. (2010). PHENIX: a comprehensive 751 
Python-based system for macromolecular structure solution. Acta Crystallographica 752 
Section D: Biological Crystallography 66, 213-221. 753 
Baggen, J., Thibaut, H., Strating, J.R., and van Kuppeveld, F.J. (2018). The life cycle of 754 
non-polio enteroviruses and how to target it. Nat Rev Microbiol, 1. 755 
Belnap, D.M., McDermott, B.M., Filman, D.J., Cheng, N., Trus, B.L., Zuccola, H.J., 756 
Racaniello, V.R., Hogle, J.M., and Steven, A.C. (2000). Three-dimensional structure of 757 
poliovirus receptor bound to poliovirus. Proceedings of the National Academy of Sciences 758 
97, 73-78. 759 
Bergelson, J.M., and Coyne, C.B. (2013). Picornavirus entry. In Viral Entry into Host Cells 760 
(Springer), pp. 24-41. 761 
Bowman, V.D., Chase, E.S., Franz, A.W., Chipman, P.R., Zhang, X., Perry, K.L., Baker, 762 
T.S., and Smith, T.J. (2002). An antibody to the putative aphid recognition site on cucumber 763 
mosaic virus recognizes pentons but not hexons. Journal of virology 76, 12250-12258. 764 
Cai, Y., Liu, Q., Huang, X., Li, D., Ku, Z., Zhang, Y., and Huang, Z. (2013). Active 765 
immunization with a Coxsackievirus A16 experimental inactivated vaccine induces 766 
neutralizing antibodies and protects mice against lethal infection. Vaccine 31, 2215-2221. 767 
CHANG, L.-Y., LIN, T.-Y., HUANG, Y.-C., TSAO, K.-C., SHIH, S.-R., KUO, M.-L., 768 
NING, H.-C., CHUNG, P.-W., and KANG, C.-M. (1999). Comparison of enterovirus 71 769 
and coxsackievirus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. 770 
The Pediatric infectious disease journal 18, 1092-1096. 771 
Chen, V.B., Arendall, W.B., Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., 772 
Murray, L.W., Richardson, J.S., and Richardson, D.C. (2010). MolProbity: all-atom 773 
structure validation for macromolecular crystallography. Acta Crystallographica Section D: 774 
Biological Crystallography 66, 12-21. 775 
Chong, P., Guo, M.-S., Lin, F.H.-Y., Hsiao, K.-N., Weng, S.-Y., Chou, A.-H., Wang, J.-R., 776 
Hsieh, S.-Y., Su, I.-J., and Liu, C.-C. (2012). Immunological and biochemical 777 
characterization of coxsackie virus A16 viral particles. PLoS One 7, e49973. 778 
Collaborative, C.P. (1994). The CCP4 suite: programs for protein crystallography. Acta 779 
crystallographica Section D, Biological crystallography 50, 760. 780 
De la Rosa-Trevín, J., Quintana, A., Del Cano, L., Zaldivar, A., Foche, I., Gutiérrez, J., 781 
Gómez-Blanco, J., Burguet-Castell, J., Cuenca-Alba, J., and Abrishami, V. (2016). Scipion: 782 
a software framework toward integration, reproducibility and validation in 3D electron 783 
microscopy. Journal of structural biology 195, 93-99. 784 
Dong, Y., Liu, Y., Jiang, W., Smith, T.J., Xu, Z., and Rossmann, M.G. (2017). Antibody-785 
induced uncoating of human rhinovirus B14. Proceedings of the National Academy of 786 
Sciences 114, 8017-8022. 787 
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. 788 
Acta Crystallographica Section D: Biological Crystallography 60, 2126-2132. 789 
Fan, C., Ye, X., Ku, Z., Kong, L., Liu, Q., Xu, C., Cong, Y., and Huang, Z. (2017). Beta-790 
propiolactone inactivation of coxsackievirus A16 induces structural alteration and surface 791 
modification of viral capsids. Journal of virology 91, e00038-00017. 792 
Ferguson, M., Wood, D.J., and Minor, P.D. (1993). Antigenic structure of poliovirus in 793 
inactivated vaccines. Journal of general virology 74, 685-690. 794 
38 | P a g e  
 
Fields, B.N., Knipe, D.M., and Howley, P.M. (2007). Fields virology, 5th edn (Philadelphia: 795 
Wolters Kluwer Health/Lippincott Williams & Wilkins). 796 
Goddard, T.D., Huang, C.C., Meng, E.C., Pettersen, E.F., Couch, G.S., Morris, J.H., and 797 
Ferrin, T.E. (2018). UCSF ChimeraX: Meeting modern challenges in visualization and 798 
analysis. Protein Science 27, 14-25. 799 
Grant, T., Rohou, A., and Grigorieff, N. (2018). cisTEM, user-friendly software for single-800 
particle image processing. Elife 7, e35383. 801 
Harris, L.J., Skaletsky, E., and McPherson, A. (1998). Crystallographic structure of an 802 
intact IgG1 monoclonal antibody. Journal of molecular biology 275, 861-872. 803 
Hewat, E.A., and Blaas, D. (2006). Nonneutralizing human rhinovirus serotype 2-specific 804 
monoclonal antibody 2G2 attaches to the region that undergoes the most dramatic changes 805 
upon release of the viral RNA. Journal of virology 80, 12398-12401. 806 
Hewat, E.A., Neumann, E., Conway, J.F., Moser, R., Ronacher, B., Marlovits, T.C., and 807 
Blaas, D. (2000). The cellular receptor to human rhinovirus 2 binds around the 5-fold axis 808 
and not in the canyon: a structural view. The EMBO journal 19, 6317-6325. 809 
Hogle, J., Chow, M., and Filman, D. (1985). Three-dimensional structure of poliovirus at 810 
2.9 A resolution. Science 229, 1358-1365. 811 
Hou, W., Yang, L., He, D., Zheng, J., Xu, L., Liu, J., Liu, Y., Zhao, H., Ye, X., and Cheng, 812 
T. (2015). Development of a coxsackievirus A16 neutralization test based on the enzyme-813 
linked immunospot assay. Journal of virological methods 215, 56-60. 814 
Ilca, S.L., Kotecha, A., Sun, X., Poranen, M.M., Stuart, D.I., and Huiskonen, J.T. (2015). 815 
Localized reconstruction of subunits from electron cryomicroscopy images of 816 
macromolecular complexes. Nat Commun 6, 8843. 817 
Johnson, J.E. (2010). Cell entry by non-enveloped viruses, Vol 343 (Springer Science & 818 
Business Media). 819 
Kimanius, D., Forsberg, B.O., Scheres, S.H., and Lindahl, E. (2016). Accelerated cryo-EM 820 
structure determination with parallelisation using GPUs in RELION-2. Elife 5, e18722. 821 
Kucukelbir, A., Sigworth, F.J., and Tagare, H.D. (2014). Quantifying the local resolution 822 
of cryo-EM density maps. Nature methods 11, 63. 823 
Laursen, N.S., Friesen, R.H., Zhu, X., Jongeneelen, M., Blokland, S., Vermond, J., van 824 
Eijgen, A., Tang, C., van Diepen, H., and Obmolova, G. (2018). Universal protection 825 
against influenza infection by a multidomain antibody to influenza hemagglutinin. Science 826 
362, 598-602. 827 
Lee, H., Cifuente, J.O., Ashley, R.E., Conway, J.F., Makhov, A.M., Tano, Y., Shimizu, H., 828 
Nishimura, Y., and Hafenstein, S. (2013). A strain-specific epitope of enterovirus 71 829 
identified by cryo-electron microscopy of the complex with fab from neutralizing antibody. 830 
Journal of virology 87, 11363-11370. 831 
Li, J.-X., Song, Y.-F., Wang, L., Zhang, X.-F., Hu, Y.-S., Hu, Y.-M., Xia, J.-L., Li, J., and 832 
Zhu, F.-C. (2016). Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 833 
vaccine against hand, foot and mouth disease in children. Expert review of vaccines 15, 834 
129-137. 835 
Li, R., Liu, L., Mo, Z., Wang, X., Xia, J., Liang, Z., Zhang, Y., Li, Y., Mao, Q., and Wang, 836 
J. (2014). An inactivated enterovirus 71 vaccine in healthy children. New England Journal 837 
of Medicine 370, 829-837. 838 
Li, Z., Wang, D., Gu, Y., Song, S., He, M., Shi, J., Liu, X., Wei, S., Li, J., and Yu, H. (2017). 839 
Crystal structures of two immune complexes identify determinants for viral infectivity and 840 
39 | P a g e  
 
type-specific neutralization of human papillomavirus. MBio 8, e00787-00717. 841 
Liu, W., Wu, S., Xiong, Y., Li, T., Wen, Z., Yan, M., Qin, K., Liu, Y., and Wu, J. (2014). 842 
Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 843 
during a large outbreak of hand, foot, and mouth disease in Central China. PloS one 9, 844 
e96051. 845 
Mao, Q., Wang, Y., Yao, X., Bian, L., Wu, X., Xu, M., and Liang, Z. (2014). Coxsackievirus 846 
A16: epidemiology, diagnosis, and vaccine. Human vaccines & immunotherapeutics 10, 847 
360-367. 848 
Mastronarde, D.N. (2003). SerialEM: a program for automated tilt series acquisition on 849 
Tecnai microscopes using prediction of specimen position. Microscopy and Microanalysis 850 
9, 1182-1183. 851 
McLellan, J.S., Chen, M., Joyce, M.G., Sastry, M., Stewart-Jones, G.B., Yang, Y., Zhang, 852 
B., Chen, L., Srivatsan, S., and Zheng, A. (2013). Structure-based design of a fusion 853 
glycoprotein vaccine for respiratory syncytial virus. Science 342, 592-598. 854 
Nishimura, Y., Shimojima, M., Tano, Y., Miyamura, T., Wakita, T., and Shimizu, H. (2009). 855 
Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nature 856 
medicine 15, 794. 857 
Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., 858 
and Ferrin, T.E. (2004). UCSF Chimera—a visualization system for exploratory research 859 
and analysis. Journal of computational chemistry 25, 1605-1612. 860 
Plevka, P., Lim, P.-Y., Perera, R., Cardosa, J., Suksatu, A., Kuhn, R.J., and Rossmann, M.G. 861 
(2014). Neutralizing antibodies can initiate genome release from human enterovirus 71. 862 
Proceedings of the National Academy of Sciences 111, 2134-2139. 863 
Punjani, A., Rubinstein, J.L., Fleet, D.J., and Brubaker, M.A. (2017). cryoSPARC: 864 
algorithms for rapid unsupervised cryo-EM structure determination. Nature methods 14, 865 
290. 866 
Ren, J., Wang, X., Hu, Z., Gao, Q., Sun, Y., Li, X., Porta, C., Walter, T.S., Gilbert, R.J., and 867 
Zhao, Y. (2013). Picornavirus uncoating intermediate captured in atomic detail. Nat 868 
Commun 4, 1929. 869 
Ren, J., Wang, X., Zhu, L., Hu, Z., Gao, Q., Yang, P., Li, X., Wang, J., Shen, X., and Fry, 870 
E.E. (2015). Structures of coxsackievirus A16 capsids with native antigenicity: 871 
implications for particle expansion, receptor binding, and immunogenicity. Journal of 872 
virology 89, 10500-10511. 873 
Robinson, C., Doane, F.W., and Rhodes, A. (1958). Report of an outbreak of febrile illness 874 
with pharyngeal lesions and exanthem: Toronto, summer 1957—isolation of group A 875 
coxsackie virus. Canadian Medical Association Journal 79, 615. 876 
Schrodinger, L. (2010). The PyMOL molecular graphics system. Version 1, 0. 877 
Shingler, K.L., Yoder, J.L., Carnegie, M.S., Ashley, R.E., Makhov, A.M., Conway, J.F., and 878 
Hafenstein, S. (2013). The enterovirus 71 A-particle forms a gateway to allow genome 879 
release: a cryoEM study of picornavirus uncoating. PLoS pathogens 9, e1003240. 880 
Studio, D. (2009). version 2.5. Accelrys Inc: San Diego, CA, USA. 881 
Walter, T.S., Ren, J., Tuthill, T.J., Rowlands, D.J., Stuart, D.I., and Fry, E.E. (2012). A plate-882 
based high-throughput assay for virus stability and vaccine formulation. Journal of 883 
virological methods 185, 166-170. 884 
Wang, C.-Y., Lu, F.L., Wu, M.-H., Lee, C.-Y., and Huang, L.-M. (2004). Fatal 885 
coxsackievirus A16 infection. The Pediatric infectious disease journal 23, 275-276. 886 
40 | P a g e  
 
Wang, X., Peng, W., Ren, J., Hu, Z., Xu, J., Lou, Z., Li, X., Yin, W., Shen, X., and Porta, 887 
C. (2012). A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. 888 
Nature structural & molecular biology 19, 424. 889 
Xiao, C., and Rossmann, M.G. (2007). Interpretation of electron density with stereographic 890 
roadmap projections. Journal of structural biology 158, 182-187. 891 
Xing, L., Tjarnlund, K., Lindqvist, B., Kaplan, G.G., Feigelstock, D., Cheng, R.H., and 892 
Casasnovas, J.M. (2000). Distinct cellular receptor interactions in poliovirus and 893 
rhinoviruses. The EMBO Journal 19, 1207-1216. 894 
Xu, K., Acharya, P., Kong, R., Cheng, C., Chuang, G.-Y., Liu, K., Louder, M.K., O’Dell, 895 
S., Rawi, R., and Sastry, M. (2018). Epitope-based vaccine design yields fusion peptide-896 
directed antibodies that neutralize diverse strains of HIV-1. Nature medicine 24, 857. 897 
Xu, L., Zheng, Q., Li, S., He, M., Wu, Y., Li, Y., Zhu, R., Yu, H., Hong, Q., and Jiang, J. 898 
(2017). Atomic structures of Coxsackievirus A6 and its complex with a neutralizing 899 
antibody. Nat Commun 8, 505. 900 
Yamayoshi, S., Yamashita, Y., Li, J., Hanagata, N., Minowa, T., Takemura, T., and Koike, 901 
S. (2009). Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nature medicine 902 
15, 798. 903 
Yan, X., Sinkovits, R.S., and Baker, T.S. (2007). AUTO3DEM—an automated and high 904 
throughput program for image reconstruction of icosahedral particles. Journal of structural 905 
biology 157, 73-82. 906 
Ye, X., Yang, L., Jia, J., Han, J., Li, S., Liu, Y., Xu, L., Zhao, H., Chen, Y., and Li, Y. (2016). 907 
Development of sandwich ELISAs that can distinguish different types of coxsackievirus 908 
A16 viral particles. Applied microbiology and biotechnology 100, 2809-2815. 909 
Zhang, K. (2016). Gctf: Real-time CTF determination and correction. Journal of structural 910 
biology 193, 1-12. 911 
Zhang, X., Shi, J., Ye, X., Ku, Z., Zhang, C., Liu, Q., and Huang, Z. (2017). Coxsackievirus 912 
A16 utilizes cell surface heparan sulfate glycosaminoglycans as its attachment receptor. 913 
Emerging microbes & infections 6, 1-7. 914 
Zheng, Q., Zhu, R., Xu, L., He, M., Yan, X., Liu, D., Yin, Z., Wu, Y., Li, Y., and Yang, L. 915 
(2019). Atomic structures of enterovirus D68 in complex with two monoclonal antibodies 916 
define distinct mechanisms of viral neutralization. Nature microbiology 4, 124. 917 
Zheng, S.Q., Palovcak, E., Armache, J.-P., Verba, K.A., Cheng, Y., and Agard, D.A. (2017). 918 
MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron 919 
microscopy. Nature methods 14, 331. 920 
Zhou, D., Zhao, Y., Kotecha, A., Fry, E.E., Kelly, J.T., Wang, X., Rao, Z., Rowlands, D.J., 921 
Ren, J., and Stuart, D.I. (2019). Unexpected mode of engagement between enterovirus 71 922 
and its receptor SCARB2. Nature microbiology 4, 414. 923 
Zhu, F., Xu, W., Xia, J., Liang, Z., Liu, Y., Zhang, X., Tan, X., Wang, L., Mao, Q., and Wu, 924 
J. (2014). Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. New 925 
England Journal of Medicine 370, 818-828. 926 
Zhu, F.-C., Meng, F.-Y., Li, J.-X., Li, X.-L., Mao, Q.-Y., Tao, H., Zhang, Y.-T., Yao, X., 927 
Chu, K., and Chen, Q.-H. (2013). Efficacy, safety, and immunology of an inactivated alum-928 
adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-929 
blind, placebo-controlled, phase 3 trial. The Lancet 381, 2024-2032. 930 
Zhu, L., Sun, Y., Fan, J., Zhu, B., Cao, L., Gao, Q., Zhang, Y., Liu, H., Rao, Z., and Wang, 931 
X. (2018a). Structures of Coxsackievirus A10 unveil the molecular mechanisms of receptor 932 
41 | P a g e  
 
binding and viral uncoating. Nat Commun 9, 4985. 933 
Zhu, L., Xu, K., Wang, N., Cao, L., Wu, J., Gao, Q., Fry, E.E., Stuart, D.I., Rao, Z., and 934 
Wang, J. (2018b). Neutralization mechanisms of two highly potent antibodies against 935 
human enterovirus 71. mBio 9, e01013-01018. 936 
Zhu, R., Xu, L., Zheng, Q., Cui, Y., Li, S., He, M., Yin, Z., Liu, D., Li, S., and Li, Z. (2018c). 937 
Discovery and structural characterization of a therapeutic antibody against coxsackievirus 938 
A10. Sci Adv 4, eaat7459. 939 
 940 
